Company Profile

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE581.252.55 (+0.44 % )
PREV CLOSE (Rs.) 578.70
OPEN PRICE (Rs.) 576.50
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 581.25 (2 )
VOLUME 18854
TODAY'S LOW / HIGH (Rs.)570.05 585.35
52 WK LOW / HIGH (Rs.)483.6 711.55
NSE581.10 4.9 (+0.85 % )
PREV CLOSE(Rs.) 576.20
OPEN PRICE (Rs.) 578.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 581.10 (45 )
VOLUME 454240
TODAY'S LOW / HIGH(Rs.) 569.65 585.95
52 WK LOW / HIGH (Rs.)493.5 711.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.34
TTM EPS (Rs.) 52.84
P/E Ratio 11.00
Book Value (Rs.) 414.85
Face Value (Rs.) 1
MCap (Rs. in Mn) 164010.24
Price/Earning (TTM) 10.21
Price/Sales (TTM) 2.60
Price/Book (MRQ) 1.40
PAT Margin (%) 15.77
ROCE (%) 11.02
Incorporation Year : 1977

Management Info :

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone :

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
26Feb02-26-2019$ Announcement under Regulation 30 (LODR)-Press Release / Media Release Announcement under Regulati
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris?, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting.
Glenmark Pharmaceuticals Announces Results from New Analysis of..
20Feb02-20-2019$ Announcement under Regulation 30 (LODR)-Press Release / Media Release Announcement under Regulati
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris?, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual MeetingGlenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris?, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data..
18Feb02-18-2019$ Announcement under Regulation 30 (LODR)-Press Release / Media Release Announcement under Regulati
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam, 0.05%
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol..
14Feb02-14-2019$ Outcome of Board Meeting Outcome of Board Meeting
Sub: Outcome of the Board Meeting - February 14, 2019 We wish to inform you that Board at its meeting held today has given an in-principle approval to spin off the innovation business into a new company in the US. Kindly find the attached media release regarding the same, which is self-explanatory.
Sub: Outcome of the Board Meeting - February 14, 2019 We wi..
11Feb02-11-2019$ Announcement under Regulation 30 (LODR)-Press Release / Media Release Announcement under Regulati
Sub: Glenmark Pharmaceuticals receives ANDA approval for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg
Sub: Glenmark Pharmaceuticals receives ANDA approval for Sevela..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit1958.7110143.47
Gross Profit 1838.28 12188.25
Operating Profit 2647.1415279.27
Net Sales 16320.3664318.84
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 7392.30 (2.83%)
M.Cap ( in Cr)
15708.12
Procter&Gamble Healt (BSE)
 4342.55 (3.17%)
M.Cap ( in Cr)
7208.36
Astrazeneca Pharma I (BSE)
 2343.00 (4.79%)
M.Cap ( in Cr)
5857.50
Piramal Enterprises (BSE)
 2133.40 (4.28%)
M.Cap ( in Cr)
42380.15
Pfizer (BSE)
 3003.70 (0.76%)
M.Cap ( in Cr)
13741.25
Shareholding Pattern More
PROMOTERS 46.54 %
MUTUAL FUNDS/UTI 4.18 %
FI/BANKS/INSURANCE 2.57 %
NON-INSTITUTION 13.9 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested